XERS: SEC Form DEF 14A filed by Xeris Biopharma Holdings Inc.
Stocks in this Quantisnow insightHealth Care
Historical context for XERS
Across the 10 sessions after earlier XERS headlines, the stock closed higher 5 times and lower 5 times, with a median move of 1.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | XERS | SPY |
|---|---|---|---|
| Apr 23, 2026 | Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026 | -1.5% | -0.4% |
| Apr 6, 2026 | Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | +0.2% | +0.5% |
| Mar 2, 2026 | Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance | -1.6% | +0.1% |
| Feb 27, 2026 | Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit | -9.2% | -0.5% |
| Feb 17, 2026 | Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026 | +1.3% | +0.2% |
| Jan 8, 2026 | Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue | +12.8% | -0.0% |
Quantisnow market dataNASDAQ
XERS
Xeris Biopharma Holdings Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Get push alerts for XERS
Full XERS profile on Quantisnow Follow XERS and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time